Key positives include strong reported profitability, a very robust balance sheet with substantial cash and almost no debt, and an established discovery platform supported by heavy ongoing R&D investment. The company has meaningful strategic flexibility thanks to its liquidity and can pursue sizable partnerships or acquisitions without endangering its financial stability. Its collaboration history with larger pharma players adds credibility and potential optionality for future deals.

Main risks center on strategic and execution uncertainty. The abrupt pivot away from cell therapy leaves the company rebuilding its pipeline, and its future now hinges on sourcing and executing the right external deals in highly competitive therapeutic areas. There are also questions around the quality of earnings and cash conversion given the conflicting cash flow data, plus the burden of restructuring costs and the possibility that high R&D spending may not translate into commercially successful medicines. Competitive pressures and regulatory or pricing challenges in immunology and oncology add further uncertainty.

GLPG appears to be at a strategic crossroads: financially strong but in the middle of redefining its business model and pipeline. In the near term, investors should expect a period dominated by restructuring, portfolio pruning, and business development announcements rather than a steady flow of late‑stage clinical readouts. The substantial cash buffer provides time to execute this pivot, but the medium‑ to long‑term outcome will depend on how effectively the company can turn its scientific platform and capital base into a differentiated, sustainable portfolio of drugs that generates real cash, not just accounting profits.